The launch of AMILI Metabolic Health, a novel synbiotic product, marks a significant advancement in the field of metabolic health, particularly for Asian populations. This groundbreaking product, developed in collaboration with Unity and Singapore's National University Hospital (NUH), leverages the unique characteristics of the Asian gut microbiome to address a pressing health concern among Asians.
A Tailored Approach to Metabolic Health
What sets AMILI Metabolic Health apart is its Asian-specific formulation, which is a result of meticulous research and analysis of microbiome data from both healthy individuals and patients with metabolic conditions. Dr. Jeremy Lim, co-founder and CEO of AMILI, emphasizes the importance of using Asian data to create solutions that are culturally relevant and effective. By studying the microbes present in individuals and their interactions, the AMILI R&D team identified four probiotic strains, including Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis, which have been shown to improve fasting blood glucose, liver function, and reduce insulin resistance.
The product also incorporates Akkermansia, a postbiotic, to enhance insulin sensitivity, total cholesterol levels, and body composition. This multi-strain approach, combined with prebiotic fiber and botanical extracts like milk thistle, showcases a comprehensive strategy to support metabolic health.
Addressing a Prevalent Health Challenge
The focus on metabolic health is particularly significant in Singapore, where chronic diseases such as diabetes, high blood pressure, and hyperlipidemia are prevalent. According to the National Population Health Survey 2024, the obesity rate has risen, and a significant proportion of residents suffer from high cholesterol and blood pressure. Dr. Lim highlights the importance of understanding the Asian-specific BMI thresholds, which are lower for obesity and overweight compared to Western populations.
Associate Professor Dan Yock Young, a senior consultant at NUH's National University Centre for Digestive Health, underscores the value of collaborations between clinical insights and microbiome science. By combining data from Singaporean patients with microbiome research, these partnerships contribute to a deeper understanding of the gut microbiome's role in health and disease, potentially leading to innovative solutions for metabolic health in Asian populations.
The Power of Synbiotics
Synbiotics, a combination of probiotics and prebiotics, are gaining recognition for their gut health benefits. While consumers are familiar with the advantages of probiotics, the concept of synbiotics for metabolic health is still relatively new. Unity, a pharmacy retail chain in Singapore, is working with pharmacists to educate the public about the benefits of microbiome supplements for metabolic health. This partnership aims to bring trusted, science-based Asian microbiome data closer to the community, promoting a healthier lifestyle for Singaporeans.
In conclusion, the launch of AMILI Metabolic Health represents a significant step towards addressing metabolic health challenges in Asia. By harnessing the power of the Asian gut microbiome and combining it with advanced research, this product offers a tailored solution for a diverse population. As the demand for personalized health solutions continues to grow, collaborations between healthcare providers, researchers, and companies like AMILI and Unity will play a crucial role in shaping the future of metabolic health in Asia.
